Item 8.01. Other Events.
On
AEVI-002 is a potential first-in-class anti-LIGHT monoclonal antibody being developed for use in Pediatric Onset Crohn's disease. The 8-week Phase Ib, open-label, multi-center, dose-escalation proof-of-concept study has been initiated and is currently recruiting and enrolling patients.
© Edgar Online, source